Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push
PositiveFinancial Markets

Novo Nordisk has entered into a significant licensing agreement worth $2.1 billion with Omeros, aimed at advancing treatments for rare diseases. This partnership highlights Novo Nordisk's commitment to expanding its portfolio in the biotechnology sector and addressing unmet medical needs. Such collaborations are crucial as they can accelerate the development of innovative therapies, ultimately benefiting patients who suffer from these conditions.
— Curated by the World Pulse Now AI Editorial System